Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The companies will develop an assay and software package for Thermo's cancer research product portfolio.
The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.
The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.